Hybrigenics Services SAS will focus on further growth of fee-for-service businesses

The Annual General Meeting on June 25, 2010 approved the creation of a subsidiary called Hybrigenics Services SAS, fully-owned by Hybrigenics SA. This business generated €3.27 million of revenue in 2009 (up 8% from the prior year) and operates independently within Hybrigenics SA. Hybrigenics Services SAS will enjoy greater independence as a separate profit center, especially in terms of access to working capital to finance an aggressive marketing and sales strategy and to fuel organic and/or potential external growth.

Hybrigenics SA will remain focussed on proprietary pharmaceutical R&D

The Phase IIa clinical development study of inecalcitol produced very promising results in terms of tolerance and presumption of efficacy in hormone-refractory prostate cancer. The maximum tolerated oral dose of inecalcitol is extremely high: 4 milligram per day. The response rate to the combination treatment with Taxotere now reached 84%: 38 patients out of 45 evaluable patients on prostate specific antigen (PSA) decline within 3 months. Patient enrolment has been completed up to 54 patients; the last treatments will take place in September.

Given this excellent tolerance, Hybrigenics SA is considering testing oral inecalcitol in other potential indications, such as severe psoriasis. Hybrigenics SA research on inhibitors of ubiquitin-specific proteases is at the forefront of
innovation in the field of novel anticancer agents acting on the ubiquitin-proteasome system. Selective inhibitors of USP7 have been identified and protected by several patent applications. Their chemical optimization is ongoing.